Navigation Links
Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
Date:6/5/2009

RECORD trial also demonstrates durable blood sugar control over time with Avandia

LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 5 /PRNewswire/ -- Clinical trial results presented today at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.

Results from the 4,447-patient Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study, which was sponsored by GlaxoSmithKline, Avandia's maker, were also published online today in the medical journal The Lancet.

RECORD is a large, prospective, randomized, controlled study that was initiated in 2001, and designed to compare cardiovascular outcomes of patients on Avandia added to metformin or sulfonylurea to those on metformin and sulfonylurea. The study confirmed its primary hypothesis. It showed that cardiovascular hospitalization or cardiovascular death (which includes heart attack, congestive heart failure, and stroke) was not statistically different between the two groups after an average of 5.5 years of therapy. This translates into 321 events (14.5 percent) among patients receiving Avandia compared to 323 events (also 14.5 percent) for patients receiving control medications (hazard ratio=0.99, 95% confidence interval=0.85 to 1.16) (Data on the individual components are provided below.)

"RECORD provides a robust assessment of rosiglitazone's cardiovascular safety and achieving the study's primary endpoint leads us to conclude that rosiglitazone carries no increased risk of overall cardiovascular death or hospitalization compared to the most commonly used diabetes medicines, metformin and sulfonylurea, which have been used for decades," said Dr. Philip D. Home, chairman of the RECORD Steering Committ
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
2. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
3. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
4. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
5. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
6. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
7. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
8. Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
9. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
10. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
11. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... the medical, research, and veterinary markets worldwide and providing ... in the United States , announced ... acquire 100% of QCR & Trio Diagnostics Limited, a ... The transaction closed on November 17, 2014. ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... N.Y. , Nov. 21, 2014  Cardinal Health, ... world,s largest health care services companies, and Henry Schein, ... provider of health care products and services to office-based ... the companies have entered into a long-term strategic agreement ... product offerings to office-based medical practices.  This strategic agreement ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... , SEELZE, Germany, Dec. ... today a multi-year distribution agreement with Pro-Lab Laboratuar Teknolojileri, ... in Turkey. , Burdick & Jackson solvents are used ... discovery and evaluation process. , "The annual growth rate ...
... ... Channel 9 recently reported that the " Help is ... financially-struggling Floridians access information on patient assistance programs that provide prescription medicines ... bus, which is part of the Partnership for Prescription Assistance ...
Cached Medicine Technology:Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 2Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 3'Help is Here Express' in Orlando to Help Floridians Afford Medicine 2
(Date:11/22/2014)... November 22, 2014 The topic of ... of block retaining walls. The article states that, “While they ... several necessary steps that go into creating this powerful look.” ... a retaining wall is choosing which kind of block matches ... , B&D Rockeries says, “The two main options are concrete ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Recently, UWDress.com ... wedding guest dresses . In addition, the company ... products. , As a leading online supplier of ... of beautiful outfits. The unusual best wedding guest gowns ... Besides the amazing designs, this new selection is famous ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 A ... was announced today which safely detects and identifies ... frequency radio waves. Developed by RHT SpectraSafe, the ... hosts broad applications in other areas including medical, ... security. , Using high frequency radio waves that ...
(Date:11/22/2014)... A Xarelto lawsuit has been filed on behalf ... million in damages from the makers and marketers of the ... the woman began using Xarelto in March 2012 and used ... she suffered life-threatening bleeding in July 2012 and as a ... emotional distress. The lawsuit purports that the woman’s injuries are ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, 2014 (HealthDay ... in an ambulance by a neurologist equipped with a CT ... patients get the clot dissolver -- tissue plasminogen activator (tPA) ... noted. For the best outcome, the drug needs to be ... researchers said. "The so-called ,golden hour, is associated with ...
Breaking Medicine News(10 mins):Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... a National CompetitionCINCINNATI, March 31 The Prilosec OTC(R) ... nation and it is giving fans the opportunity to ... win tickets to upcoming NASCAR(R) Sprint Cup Series(TM) races. ... across the country will be firing up their grills ...
... ... be available in one year-,BELLEVILLE, ON, March 31 ... a research-based, technology-driven Canadian biopharmaceutical company, today announced ... Phase III registration trial evaluating Urocidin(TM) in the ...
... of potential medical problemsHONOLULU, March 31 A new ... there are significant benefits for patients and nurses when ... "The outcomes were definitive," stated Dr. Patrick Sullivan, President ... monitoring provides an early alert to RNs about potential ...
... Health Care Provides Extensive Services & SupportSAN FRANCISCO, March ... of in home support and recovery services has announced ... Interim HomeStyle Services first opened its San Francisco ... to help people remain independent as they age or ...
... Wilhelm uses latest technology to give patients the ability to improve smile ... ... Dr. Wilhelm, DMD MSD, announced today that he is providing patients with ... giving patients the appearance of a perfect set of teeth and an ...
... Urgent Care Center. Hoboken residents now have much needed option for treatment ... ... -- Hoboken families now have a convenient place to go for most ... Hoboken,s first Urgent Care center and a medical facility like no other ...
Cached Medicine News:Health News:Prilosec OTC(R) Fires Up A BBQ Tour for NASCAR(R) Fans 2Health News:Prilosec OTC(R) Fires Up A BBQ Tour for NASCAR(R) Fans 3Health News:Prilosec OTC(R) Fires Up A BBQ Tour for NASCAR(R) Fans 4Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 3Health News:Study Shows Patients & Nurses Benefit From Continuous Vigilance Monitoring 2Health News:Nation's Largest Home Care Provider Welcomes New Management Team to San Francisco Office 2Health News:Dr. Wilhelm, DMD MSD, Makes Clients Smile with New Easy Smile Dental Appliance 2Health News:Dr. Wilhelm, DMD MSD, Makes Clients Smile with New Easy Smile Dental Appliance 3Health News:PromptMD Announces the Opening of their First Urgent Care Center at 309 First Street in Hoboken 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: